CRISPR/Cas9

CRISPR/Cas9 Products

  • All (10)
  • CRISPR/Cas9 Inhibitors (2)
  • CRISPR/Cas9 Activators (7)
  • CRISPR/Cas9 Modulator (1)
  • New CRISPR/Cas9 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2638 NU7441 (KU-57788) NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
Nucleic Acids Res, 2024, gkad1224
Theranostics, 2024, 14(4):1561-1582
SSRN, 2024, 12 Pages
S2775 Nocodazole Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Life Sci Alliance, 2024, 7(4)e202302257
Nat Metab, 2023, 5(2):277-293
Adv Sci (Weinh), 2023, 10(7):e2205566
S7046 Brefeldin A (BFA) Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Nat Commun, 2024, 15(1):203
Commun Biol, 2024, 7(1):161
Cancer Immunol Immunother, 2024, 73(1):7
S7742 SCR7 SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
iScience, 2024, 27(2):108814
Nat Commun, 2023, 14(1):4761
Mol Ther Nucleic Acids, 2023, 31:309-323
S7827 4-Hydroxytamoxifen (Afimoxifene) 4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
Cancers (Basel), 2024, 16(3)678
Nat Commun, 2023, 14(1):5400
Nat Commun, 2023, 14(1):5400
S2579 Zidovudine Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.
bioRxiv, 2024, 10.1101/2024.01.22.576652
Invest Ophthalmol Vis Sci, 2023, 64(5):3
Cancer Discov, 2022, candisc.1117.2021
S7974 L755507 L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
bioRxiv, 2023, 10.1101/2023.10.03.560773
Genesis, 2022, 60(1-2):e23465
Chembiochem, 2021, 22(20):2957-2965
S8234 RS-1 RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
Int J Biol Sci, 2021, 17(4):1026-1040
Chembiochem, 2021, 22(20):2957-2965
S8844 BRD0539 BRD0539 is a potent inhibitor of Streptococcus pyogenes Cas9 (SpCas9) with IC50 of 22 μM in an in vitro DNA cleavage assay.
Mol Cell, 2021, S1097-2765(21)00168-4
S0102 L 189 L 189 is a novel human DNA ligase inhibitor with IC50 of 5 μM, 9 μM and 5 μM for hLigI, hLigIII and hLigIV, respectively. L 189 inhibits base excision repair (BER) and non-homologous end joining (NHEJ). L 189 specifically sensitizes cancer cells to DNA damage.
S8844 BRD0539 BRD0539 is a potent inhibitor of Streptococcus pyogenes Cas9 (SpCas9) with IC50 of 22 μM in an in vitro DNA cleavage assay.
Mol Cell, 2021, S1097-2765(21)00168-4
S0102 L 189 L 189 is a novel human DNA ligase inhibitor with IC50 of 5 μM, 9 μM and 5 μM for hLigI, hLigIII and hLigIV, respectively. L 189 inhibits base excision repair (BER) and non-homologous end joining (NHEJ). L 189 specifically sensitizes cancer cells to DNA damage.
S2638 NU7441 (KU-57788) NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
Nucleic Acids Res, 2024, gkad1224
Theranostics, 2024, 14(4):1561-1582
SSRN, 2024, 12 Pages
S2775 Nocodazole Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Life Sci Alliance, 2024, 7(4)e202302257
Nat Metab, 2023, 5(2):277-293
Adv Sci (Weinh), 2023, 10(7):e2205566
S7046 Brefeldin A (BFA) Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Nat Commun, 2024, 15(1):203
Commun Biol, 2024, 7(1):161
Cancer Immunol Immunother, 2024, 73(1):7
S7742 SCR7 SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
iScience, 2024, 27(2):108814
Nat Commun, 2023, 14(1):4761
Mol Ther Nucleic Acids, 2023, 31:309-323
S7827 4-Hydroxytamoxifen (Afimoxifene) 4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
Cancers (Basel), 2024, 16(3)678
Nat Commun, 2023, 14(1):5400
Nat Commun, 2023, 14(1):5400
S7974 L755507 L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
bioRxiv, 2023, 10.1101/2023.10.03.560773
Genesis, 2022, 60(1-2):e23465
Chembiochem, 2021, 22(20):2957-2965
S8234 RS-1 RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
Int J Biol Sci, 2021, 17(4):1026-1040
Chembiochem, 2021, 22(20):2957-2965
S2579 Zidovudine Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.
bioRxiv, 2024, 10.1101/2024.01.22.576652
Invest Ophthalmol Vis Sci, 2023, 64(5):3
Cancer Discov, 2022, candisc.1117.2021

Choose Selective CRISPR/Cas9 Inhibitors

Tags: CRISPR/Cas9 enhancer|CRISPR/Cas9 activator|CRISPR/Cas9 inhibitor